Emerging markets are benefiting from enhanced healthcare infrastructure, boosting access to CMV diagnostics and treatments. Furthermore, advancements in personalized medicine and vaccine development, ...

The impact of prophylactic oral ganciclovir therapy on the incidence of cytomegalovirus (CMV) disease, patient and graft survival, and costs in patients receiving kidney and liver transplants is ...

Cytomegalovirus (CMV) is a ubiquitous herpesvirus that, while often latent in the general population, can become reactivated in individuals with compromised immune systems. Inflammatory bowel disease ...

Patients with cystic fibrosis who had cytomegalovirus had earlier times to lung transplant referral and reaching final stages of disease. Researchers have identified a potential explanation for why ...

The pharmacology, pharmacokinetics, safety, and efficacy of valganciclovir, an oral prodrug for ganciclovir, used to prevent cytomegalovirus (CMV) disease in solid organ transplant recipients are ...

Prevymis, a non-nucleoside CMV inhibitor (3,4 dihydro-quinazoline), inhibits viral replication through targeting the viral terminase complex. Merck announced that the Food and Drug Administration (FDA ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the presentation of findings from a systematic literature review and ...

Background. Human cytomegalovirus (CMV) is prevalent in older adults and has been implicated in many chronic diseases of aging. This study investigated the relation between CMV and the risk of ...

This is a preview. Log in through your library . Abstract Cytomegalovirus (CMV) viremia and excretion from the oropharynx and urine were examined for their utility in predicting the development of CMV ...

Congenital cytomegalovirus is the most common nongenetic cause of hearing loss in childhood, yet many parents do not know ...